BioCentury
ARTICLE | Clinical News

4SC-202: Phase I data

July 14, 2014 7:00 AM UTC

Top-line data from the open-label, dose-escalation, German Phase I TOPAS trial in 24 patients with advanced hematological malignancies showed that 25-400 mg oral 4SC-202 for 14 days in 21-day cycles l...